Announcements Trials
Browse Landscape

Phase

Phase 4 1Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Ovarian Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

Letrozole 23Docetaxel 17Cyclophosphamide 13Zoledronic Acid 12Trastuzumab 12Anastrozole 12exemestane 11Tamoxifen 11Paclitaxel 11Capecitabine 10Fulvestrant 8Epirubicin 8pegfilgrastim 7Saline Solution 7Bupivacaine 7pertuzumab 6liposomal doxorubicin 6abemaciclib 6Sodium Chloride 6Filgrastim 6Carboplatin 6pegylated granulocyte colony-stimulating factor 5palbociclib 5Ropivacaine 5Dexmedetomidine 5Bevacizumab 5ribociclib 4eribulin 4Vinorelbine 4Tranexamic Acid 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × LY 353381 × Breast × Clear all
NCT00190697 2007-05-25

A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment

Eli Lilly and Company

Phase 4 Completed
70 enrolled
BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡